Zydus Cadila to seek nod for two-dose regimen of its approved vaccine in India
Considering the burden on healthcare and the expense of buying three doses, Zydus Cadila is planning to seek approval for the two-dose regimen of its needle-free COVID-19 vaccine, ZyCoV-D, days after the vaccine was approved by India’s drugs regulator for emergency use in India on August 20.
By : migrator
Update: 2021-09-13 04:18 GMT
New Delhi
The trials for the two-dose regimen are underway. 2mg of the vaccine has been prescribed in each dose of the present-day three-dose vaccine i.e. total of 6 mg. The company is now evaluating a 2 dose regime with 3mg in each dose. The vaccine is said to be pathbreaking as it is for the first time that a technologically advanced vaccine has been successfully developed on the Plasmid DNA platform for human use.
Visit news.dtnext.in to explore our interactive epaper!
Download the DT Next app for more exciting features!
Click here for iOS
Click here for Android